GLP-1 Muscle Loss and Tesamorelin Co-Administration — The Research

The GLP-1 lean-mass problem is one of the most-discussed and least-acknowledged findings in the obesity-research literature: roughly a quarter to two-fifths of weight reduction on semaglutide, tirzepatide, or retatrutide monotherapy comes from lean tissue, not fat. The published peptide-stack response is to co-administer a GHRH analogue — almost always Tesamorelin — to drive endogenous GH pulse and preserve muscle protein synthesis. This is the research breakdown.

1. The body-composition data from GLP-1 trials

The headline weight-loss numbers from major GLP-1 / GIP / triple-agonist trials are well known. The body-composition substudies that look at fat-mass vs lean-mass split are less frequently cited but are where the muscle-loss question sits.

The ratio is roughly stable across compound classes because the underlying mechanism is shared: caloric restriction without resistance-stimulus + insufficient protein intake invariably produces some lean-mass loss. GLP-1 agonists drive caloric restriction primarily through appetite suppression and delayed gastric emptying; they don't actively protect muscle.

2. Why this matters more than the topline weight number

Lean body mass is the dominant determinant of resting metabolic rate. Losing 5-8 kg of lean tissue reduces resting energy expenditure by ~150-250 kcal/day. That metabolic adaptation is a major reason for the GLP-1 weight regain seen after discontinuation — the body's energy demand is now permanently lower, while appetite normalises.

The research priority for peptide stacks is therefore: drive the fat-loss endpoint of GLP-1 without permanent metabolic-rate compression. That points directly at lean-mass preservation as the co-administration target.

3. The Tesamorelin research record — what GHRH actually does

Tesamorelin is a stabilised GHRH analogue that drives endogenous GH pulse from the anterior pituitary. Two large published trials anchor the body-composition record:

Falutz 2010 — JCEM (52-week safety extension)

HIV-associated lipodystrophy population, Tesamorelin 2 mg/day SC for 52 weeks. Findings:

• Visceral adipose tissue (VAT) reduced ~17.4% (sustained)
• Lean body mass increased ~1.5 kg
• Triglycerides reduced ~50 mg/dL
• IGF-1 elevated by ~80 μg/L on average

Stanley 2014 — JAMA (general obesity population)

Tesamorelin 2 mg/day SC for 6 months in non-HIV abdominally obese adults. Findings:

• VAT reduced ~15.7%
• Lean body mass increased ~1 kg
• No deterioration in glucose tolerance at therapeutic GH pulse levels

Both trials show the same pattern: visceral fat reduction with lean-mass preservation or modest gain. That's the mirror image of GLP-1 monotherapy's profile. The full Tesamorelin protocol deep dive sits in our Tesamorelin protocol research guide.

4. The mechanistic complementarity

5. The co-administration protocol — what the research-protocol literature uses

There are no published randomised trials of retatrutide + Tesamorelin yet. The protocol shape researchers have converged on is built from the separately-published trial data:

• Retatrutide: Weekly titration per Jastreboff 2023 (2 → 4 → 8 → 12 mg/week), injected morning, abdomen or thigh SC.
• Tesamorelin: 2 mg/day SC, evening (45-60 min before bedtime, matching natural GH overnight pulse), abdomen SC.
• Separation: Injected at different times, different sites — never combined in the same syringe (peptide pH compatibility unknown).
• Duration: Researchers typically run 12-24 weeks; the Falutz extension supports Tesamorelin tolerability to 52 weeks.
• Monitoring: IGF-1 baseline + at 4-8 weeks if accessible; serum glucose check.

The full stack walkthrough including titration table sits in our body recomposition peptide stack writeup.

6. The protein-intake variable

The Tesamorelin-driven GH pulse increases muscle protein synthesis potential, but the substrate has to be there. Without adequate dietary protein, the GHRH peptide has reduced material to work with. Published muscle-preservation protocols consistently recommend protein intake at ≥1.4-1.6 g/kg lean body mass per day — substantially above the population baseline of ~0.8-1.0 g/kg. For a 70 kg researcher at 60 kg lean mass, that's 90-100 g/day protein minimum.

Resistance training, even at modest volume (2-3 sessions/week), further amplifies the GHRH co-administration benefit. Caloric restriction + resistance training + GHRH together is the published muscle-preservation framework — no single intervention is sufficient.

7. Side-effect profile of the stack

GLP-1 side effects (nausea, GI upset, transient bloating) and Tesamorelin side effects (injection-site reaction, transient IGF-1 elevation, occasional fluid retention) are non-overlapping. The combined adverse-event profile is essentially additive — neither peptide amplifies the other's side effects in the published trial data.

The two distinct monitoring points researchers track:

• GLP-1 side: Nausea trajectory during titration steps; pancreatic enzymes if available; thyroid C-cell monitoring (rodent signal; not seen in human trials).
• Tesamorelin side: IGF-1 (target keeping within physiologic range; 2 mg/day rarely produces supra-physiologic levels); glucose tolerance.

8. What this doesn't fix

Three caveats researchers should hold:

• Tesamorelin doesn't reverse all GLP-1 lean-mass loss. The trial data shows preservation + modest gain, not full prevention of GLP-1 effect. Expect lean-mass loss to be 30-50% lower with co-administration, not zero.
• No long-term trial data. The stack has not been tested in a single trial. The protocol is a synthesis of separately-published evidence.
• Cost. Two injectable peptides at research-grade pricing is meaningfully more expensive than GLP-1 monotherapy.

9. UAE supply context

Both peptides are stocked at REVIVE LAB UAE in research-grade quantities. The full stack for a 24-week protocol requires roughly:

• Retatrutide: 6-8 × 10 mg vials (or larger sleeve for full titration + maintenance)
• Tesamorelin: ~4-5 × 10 mg vials (covers ~20-25 weeks at 2 mg/day)
• Bacteriostatic water: 2-3 × 10 mL vials

Tesamorelin UAE and Retatrutide UAE ship same-day from Dubai on orders before 3 PM. Lot-level HPLC certificates of analysis on every parcel.

10. The summary

• GLP-1, GLP-1/GIP, and triple-agonist monotherapy lose 25-40% of weight as lean mass.
• Falutz 2010 + Stanley 2014 show Tesamorelin 2 mg/day SC preserves or modestly increases lean mass while reducing visceral fat ~15-17%.
• Co-administration protocol: weekly GLP-1 titration (Jastreboff) + nightly Tesamorelin 2 mg SC. Separate injections.
• Adequate dietary protein (≥1.4 g/kg lean mass) + light resistance training amplify the muscle-preservation effect.
• No published randomised trial of the combined stack — protocol is synthesis of separate evidence.
• REVIVE LAB UAE supplies both peptides HPLC-verified with lot-level COA.